Mostrar el registro sencillo del ítem

Modulation of GLP-1 signaling as a novel therapeutic approach in the treatment of Alzheimer’s disease pathology

dc.contributor.authorTramutola A.
dc.contributor.authorArena A.
dc.contributor.authorCini C.
dc.contributor.authorButterfield D.A.
dc.contributor.authorBarone E.
dc.date.accessioned2020-09-02T22:29:22Z
dc.date.available2020-09-02T22:29:22Z
dc.date.issued2017
dc.identifier10.1080/14737175.2017.1246183
dc.identifier.citation17, 1, 59-75
dc.identifier.issn14737175
dc.identifier.urihttps://hdl.handle.net/20.500.12728/6432
dc.descriptionIntroduction: Clinical studies suggest a link between peripheral insulin resistance and cognitive dysfunction. Post-mortem analyses of Alzheimer disease (AD) subjects revealed insulin resistance in the brain, suggesting a role of this condition in cognitive deficits observed in AD. In this review, we focus on the glucagon-like peptide-1 (GLP-1) signaling pathway, whose role in the brain is collecting increasing attention because of its association with insulin signaling activation. Areas covered: The role of GLP-1-mediated effects in the brain and how they are affected along the progression of AD pathology is discussed. Furthermore, we provide a comprehensive discussion about the use of GLP-1 mimetics drugs, which have been developed as a treatment for T2DM but seem to possess a number of other physiological properties, including neuroprotective and anti-inflammatory effects, that may be useful to slow AD progression. Expert commentary: The repurposing of antidiabetic drugs for the modulation of brain insulin resistance in AD appears to be of great interest. The beneficial effects on synaptogenesis, neurogenesis, and cell repair as well as the reduction of the chronic inflammatory response, and most importantly the reduction of amyloid plaques in the brain indicate that these drugs have promise as novel treatments for AD. © 2016 Informa UK Limited, trading as Taylor & Francis Group.
dc.language.isoen
dc.publisherTaylor and Francis Ltd
dc.subjectAlzheimer disease
dc.subjectdementia
dc.subjectGLP-1
dc.subjectincretins
dc.subjectinsulin resistance
dc.subjectantidiabetic agent
dc.subjectdipeptidyl peptidase IV inhibitor
dc.subjectglucagon like peptide 1
dc.subjectliraglutide
dc.subjectantidiabetic agent
dc.subjectglucagon like peptide 1
dc.subjectAlzheimer disease
dc.subjectamyloid plaque
dc.subjectantiinflammatory activity
dc.subjectcell regeneration
dc.subjectdisease course
dc.subjecthuman
dc.subjectinsulin resistance
dc.subjectnervous system development
dc.subjectneuroprotection
dc.subjectnonhuman
dc.subjectprotein function
dc.subjectReview
dc.subjectsignal transduction
dc.subjectsynaptogenesis
dc.subjectAlzheimer disease
dc.subjectdrug effects
dc.subjectmetabolism
dc.subjectmolecularly targeted therapy
dc.subjectsignal transduction
dc.subjectAlzheimer Disease
dc.subjectGlucagon-Like Peptide 1
dc.subjectHumans
dc.subjectHypoglycemic Agents
dc.subjectInsulin Resistance
dc.subjectMolecular Targeted Therapy
dc.subjectSignal Transduction
dc.titleModulation of GLP-1 signaling as a novel therapeutic approach in the treatment of Alzheimer’s disease pathology
dc.typeReview


Ficheros en el ítem

Thumbnail
Nombre:
item_2-s2.0-85004024046.pdf
Tamaño:
3.393Kb
Formato:
PDF
Ver/

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem